Psoriatic Arthritis Therapeutics - Pipeline Analysis 2018

Psoriatic Arthritis Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS10982
Available Format:

The number of drug candidates in pipeline for psoriatic arthritis are expected to increase on account of increase in the prevalence of psoriasis, globally. Psoriasis is the skin disease which is more common in Caucasian as compared to the African American and Asian Americans. The disease is symptomatized by white and scaly red patches. The prevalence of psoriatic arthritis has been increasing mainly in the patients, who are more susceptible to infection that may activate their immune system. Increase in mortality rate, other inflammatory disease complication and awareness regarding health issues are the main reasons, that are responsible for the growth of psoriatic arthritis therapeutics pipeline. According to the data published by National Institute of Health in 2014, the incidence of psoriatic arthritis ranged from 0.1 out of 100000 people in Japan to 23.1 out of 100000 people in Finland, in the Europe and America the prevalence of psoriatic arthritis varied from 0.02-0.42% of the total population. Indians have highest prevalence of psoriatic arthritis in, Singapore’s multi-ethnic population.

Psoriatic arthritis is a chronic inflammatory disease which involves inflammation of skin, synovial tissue and usually gives seronegative results for rheumatoid factor. Other complex diseases which are associated with psoriatic arthritis include ankylosing spondylitis, arthritis associated with inflammatory bowel disease and reactive arthritis. The psoriatic arthritis is diagnoses is done on the basis of the medical or family history and physical examinations such as magnetic field resonance imaging and x-ray of the affected joints. Currently, researchers are looking for better ways to diagnose psoriatic arthritis accurately, since at times a lot of similarity exist between psoriatic arthritis and other inflammatory form of arthritis. Contrast-enhanced MRI has also been developed by the researchers that can differentiate between psoriatic arthritis and rheumatoid arthritis in hand and wrist.

Novartis AG is in the process of conducting trials on demonstrating the safety and efficacy of biological Secukinumab for the treatment of psoriatic arthritis, which is currently in its Phase III of development. UCB SA. plans to introduce a drug by the name Bimekizumab, which is under Phase II stage of clinical development in patients with psoriatic arthritis, who provided inadequate responses to anti-rheumatic drug.

In December 2016, Almirall SA. and Nuevolution A/S entered into global strategic collaboration for commercialization and development of Nuevolution’s novel RORγt inverse agonist (inhibitor) for the treatment of psoriatic arthritis as well as skin inflammatory disease. Nuevolution A/S received an upfront payment of EUR 11.2 million (SEK 109.4 million), and was also eligible to receive development and regulatory milestone payments of up to in total maximum of EUR 172 million (SEK 1.7 billion) which provided successful development of RORγt inverse agonist (inhibitor), and tiered commercial sales milestones, of up to in total maximum of EUR 270 million (SEK 2.6 billion). Nuevolution A/S would further be entitled to receive tiered royalties on future net sales. In March 2016, AbbVie, Inc. and Boehringer Ingelheim GmbH signed an agreement for the development and commercialization of BI 655066, an anti-IL-23 monoclonal biologic antibody, which is currently in its Phase III stage of clinical development for psoriasis. BI 655066 is also under investigation for the development of therapy against psoriatic arthritis and crohn’s disease. Under the terms of the license agreement, AbbVie made an initial upfront payment of $595 million. Boehringer Ingelheim GmbH was eligible to receive additional development and regulatory milestone payments and royalties on net sales, the terms of which are not disclosed. In the initial period, the companies would share the responsibility for future development of BI 655066.

Some of the companies having a pipeline of Psoriatic arthritis therapeutics include Novartis AG, Amgen Plc, Galapagos NV, AbbVie, Inc., Pfizer, Inc., Celgene Corporation, Janssen Pharmaceutical K.K.

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry